Adult and pediatric patients with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas that are not amenable ...
Neurofibromatosis type 1 (NF1) is the most common of the three types of neurofibromatosis ... This often includes surgery to remove or reduce the size of neurofibromas and the evaluation and ...
GlobalData on MSN2d
FDA approves Gomekli as first neurofibromatosis drug for adultsThe US Food and Drug Administration (FDA) has approved SpringWorks Therapeutics’ Gomekli (mirdametinib) to treat ...
Adam Pearson used his neurofibromatosis struggles to succeed in acting and advocacy, inspiring others to accept differences ...
The FDA on Tuesday signed off on SpringWorks Therapeutics’ mirdametinib—now to carry the brand name Gomekli—for the treatment ...
This phase II open label study will evaluate children ≥ 1 year of age and adults with neurofibromatosis type-1 (NF1) and plexiform neurofibromas ... Because 4 of the first 11 enrolled subjects chose ...
The kinase inhibitor is now approved for adults and children aged ≥ 2 years with neurofibromatosis type 1 who have unresectable symptomatic plexiform neurofibromas.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback